

FF-10502 biochemical

FF-10502

CATALOG #
AAA227953


PRODUCT SYNONYMS

FF-10502; FF-10502 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	184302-49-6
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1]. Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1]. Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg. Administration: Tail vein injection; once weekly; for 4 weeks. Result: Suppressed tumor growth in a dose-dependent manner in mice.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
BAY-6672, CAS 2247517-53-7



Structure
BAY-6672, CAS 2247517-53-7

ADDITIONAL INFORMATION

Related Product Information for FF-10502 biochemical	FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase alpha and beta. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells.
References	1. Beck H, et al. Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). J Med Chem. 2020 Oct 22;63(20):11639-11662.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

